The ultimate goal of curative anti-cancer therapies : inducing an adaptive anti-tumor immune response

The ultimate goal of curative anti-cancer therapies : inducing an adaptive anti-tumor immune response

Bibliographic Details
Main Authors:	Wolf Hervé eFridman, Jean-Luc eTEILLAUD, Catherine eSautès-Fridman, Franck ePagès, Jérôme eGalon, Jessica eZucman-Rossi, Eric eTartour, Laurence eZITVOGEL, Guido eKroemer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2011-12-01
Series:	Frontiers in Immunology
Subjects:	cancer therapies tumor immunity anti-tumor
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fimmu.2011.00066/full

Similar Items

The grand challenges to cellular and molecular oncology
by: Lorenzo eGalluzzi, et al.
Published: (2011-03-01)

Past, present and future of molecular and cellular oncology
by: Lorenzo eGalluzzi, et al.
Published: (2011-03-01)

Frontiers in Tumor Immunity : Grand Challenge Cancer and Immunity : a family drama
by: Wolf Hervé eFridman, et al.
Published: (2011-08-01)

Cell death signaling and anticancer therapy
by: Lorenzo eGalluzzi, et al.
Published: (2011-05-01)

Cross-reactivity between cancer and microbial antigens
by: Laurence Zitvogel, et al.
Published: (2021-01-01)

Influence of tumor location on the composition of immune infiltrate and its impact on patient survival. Lessons from DLBCL and animal models.
by: Claire eGaland, et al.
Published: (2012-05-01)

Grand Challenge « Tumor immunology, towards a success story ? »
by: Catherine eSautès-Fridman
Published: (2015-02-01)

Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells
by: Mélanie eGillard-Bocquet, et al.
Published: (2013-02-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
by: Oliver Kepp, et al.
Published: (2020-01-01)

Failure of immunosurveillance accelerates aging
by: Maria Perez-Lanzon, et al.
Published: (2019-04-01)

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
by: Abhishek D Garg, et al.
Published: (2015-11-01)

Targeting the intracellular environment in cystic fibrosis: restoring autophagy as a novel strategy to circumvent the CFTR defect
by: Valeria Rachela Villella, et al.
Published: (2013-01-01)

The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
by: Lisa Derosa, et al.
Published: (2018-06-01)

COVID-19: a challenge for oncology services
by: Bertrand Routy, et al.
Published: (2020-01-01)

Natural Killer cells in non-hematopoietic malignancies
by: Mélanie eDesbois, et al.
Published: (2012-12-01)

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts
by: Gautier Stoll, et al.
Published: (2018-10-01)

Control of the adaptive immune response by tumor vasculature
by: Laetitia eMauge, et al.
Published: (2014-03-01)

Corrigendum: Combinatorial strategies for the induction of immunogenic cell death
by: Lucillia eBezu, et al.
Published: (2015-06-01)

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
by: David P. Enot, et al.
Published: (2018-09-01)

Trial watch: STING agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: TLR3 agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: IDO inhibitors in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Mitophagy: An Emerging Role in Aging and Age-Associated Diseases
by: Guo Chen, et al.
Published: (2020-03-01)

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
by: Mariona Cabo, et al.
Published: (2017-12-01)

Pro-necrotic molecules impact local immunosurveillance in human breast cancer
by: Gautier Stoll, et al.
Published: (2017-04-01)

Trial Watch: Adoptively transferred cells for anticancer immunotherapy
by: Carole Fournier, et al.
Published: (2017-11-01)

Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion
by: Elke eEggenhofer, et al.
Published: (2012-09-01)

B709 Mitochondrial Control of Cell Death
by: Guido Kroemer
Published: (2001-01-01)

Heat Shock Protein 70 Neutralizes Apoptosis-Inducing Factor
by: Guido Kroemer
Published: (2001-01-01)

Trial watch: dietary interventions for cancer therapy
by: Sarah Lévesque, et al.
Published: (2019-07-01)

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
by: Francesca Castoldi, et al.
Published: (2019-01-01)

Control of the immune response by proangiogenic factors
by: Thibault eVORON, et al.
Published: (2014-04-01)

Contribution of annexin A1 to anticancer immunosurveillance
by: Elisa Elena Baracco, et al.
Published: (2019-11-01)

BML-265 and Tyrphostin AG1478 Disperse the Golgi Apparatus and Abolish Protein Transport in Human Cells
by: Gaelle Boncompain, et al.
Published: (2019-10-01)

Trial watch: Dendritic cell-based anticancer immunotherapy
by: Abhishek D. Garg, et al.
Published: (2017-07-01)

A genotype-phenotype screening system using conditionally immortalized immature dendritic cells
by: Liwei Zhao, et al.
Published: (2021-09-01)

ONCOUROLOGICAL MULTIDISCIPLINARY TEAM IS A CONTEMPORARY FORM OF ACTIVE COLLEGIAL COOPERATION BETWEEN THE CLINICIANS AND PATHOLOGISTS
by: E. Fridman
Published: (2018-03-01)

Dynamical Boolean Modeling of Immunogenic Cell Death
by: Andrea Checcoli, et al.
Published: (2020-11-01)

Mitochondrial cell death control in familial Parkinson disease.
by: Guido Kroemer, et al.
Published: (2007-07-01)